Dr Reddy's Laboratories Profit Margin 2006-2020 | RDY

Current and historical gross margin, operating margin and net profit margin for Dr Reddy's Laboratories (RDY) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Dr Reddy's Laboratories net profit margin as of June 30, 2020 is 10.26%.
Dr Reddy's Laboratories Annual Profit Margins
Dr Reddy's Laboratories Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $10.179B $2.316B
Doctor Reddy's is an emerging global pharmaceutical company with proven research capabilities. They are vertically integrated with a presence across the pharmaceutical value chain. They produce finished dosage forms, active pharmaceutical ingredients and biotechnology products and market them globally, with focus on India, US, Europe and Russia. They conduct research in the areas of cancer, diabetes, cardiovascular, inflammation and bacterial infection
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $12.888B 4.78
Mylan (MYL) United States $8.437B 3.63
Bausch Health Cos (BHC) Canada $6.738B 4.46
ASPEN PHARMACR (APNHY) South Africa $3.382B 0.00
BridgeBio Pharma (BBIO) United States $3.350B 0.00
Supernus Pharmaceuticals (SUPN) United States $1.205B 10.57
Amphastar Pharmaceuticals (AMPH) United States $0.963B 49.64
Assembly Biosciences (ASMB) United States $0.727B 0.00
Personalis (PSNL) United States $0.669B 0.00
Homology Medicines (FIXX) United States $0.619B 0.00
Voyager Therapeutics (VYGR) United States $0.385B 0.00
CymaBay Therapeutics (CBAY) United States $0.362B 0.00
Sol-Gel Technologies (SLGL) Israel $0.161B 0.00
Mallinckrodt Public Limited Company (MNK) United Kingdom $0.137B 0.20
Zynerba Pharmaceuticals (ZYNE) United States $0.104B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.073B 0.00
China Pharma Holdings (CPHI) China $0.021B 0.00
Teligent (TLGT) United States $0.012B 0.00